Sodium Acetate

Summary

Sodium Acetate (CHEMBL1354) is an approved small molecule (ATC B05XA08); indicated across 5 conditions including ornithine carbamoyltransferase deficiency and brain neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B05XA08
• Indications: 5 conditions
• Clinical trials: 1
• Chemistry: 59.04 Da · C2H3O2-

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1354
Name	Sodium Acetate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	175
ChEBI	CHEBI:32954
ATC	B05XA08
Molecular formula	C2H3O2-
Molecular weight	59.04
InChIKey	QTBSBXVTEAMEQO-UHFFFAOYSA-M

SMILES: CC(=O)[O-]

IUPAC name: acetate

Also known as: Acetic acid, sodium salt (1:1), E-262(I), E262, FEMA NO. 3024, INS NO.262(I), INS-262(I), NSC-77459, Sodium acetate, Sodium acetate (3h2o), Sodium acetate anhydrous, Sodium acetate component of procalamine, Sodium acetate hydrate

Parent form; salt/anhydrous children: CHEMBL2107054

Patent coverage: 221,447 distinct patent families (594,259 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Carbonic anhydrase 1, Carbonic anhydrase.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ornithine carbamoyltransferase deficiency	3	MONDO:0010703	EFO:0007409
brain neoplasm	2	MONDO:0021211	EFO:0003833
stroke disorder	2	MONDO:0005098	EFO:0000712

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05345171	PHASE3	ACTIVE_NOT_RECRUITING	Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).